Health Condition 1: null- Vitiligo
Conditions
Interventions
Intervention1: Progressive non-segmental vitiligo: On NB-UVB therapy for 3 sessions per week for a duration of 6 months.
Control Intervention1: non-progressive non-segmental vitiligo: On NB-UVB therap
Sponsors
All India Institute of Medical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients of either sex, aged 15-60 years with a clinical diagnosis of non-segmental vitiligo with any of the following features â?? a. Involving >5 % BSA b. Involving 2-5 % BSA, but multi-focal, scattered lesions confined to non-contiguous areas of the body 2. With no systemic and no topical treatment for 1 month. 3. These patients will be divided into two groups. a. Progressive vitiligo - >5 new lesions in past 1 month or >15 new lesions in past 3 months, b. Non-progressive vitiligo - no new lesions in the past 6 months.
Exclusion criteria
Exclusion criteria: 1) Segmental vitiligo 2) Vitiligo involving > 50 % BSA 3) Pregnant and lactating females 4) History of photosensitivity / photo-aggravated dermatomes like SLE, xeroderma pigmentosum, basal cell nevus syndrome, prior history of skin carcinoma, photosensitive disorders, contact photosensitive substances, photosensitizing medications with an action spectrum with the corresponding UVA or UVB wave-lengths etc. 5) Inability to attend dermatology clinic for 3 sessions per week (or at least 2 sessions per week) for NB-UVB phototherapy 6) Lip-tip vitiligo or acrofacial variant only with tips of fingers and toes and lip involvement 7) Pure mucosal vitiligo 8) Patients with immuno-compromised states, like HIV/AIDS etc. 9) Patients with malignancies (cutaneous and internal)
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| 1. To assess and compare the improvement in quality of life as measured by Vitiligo Impact Scale â?? 22 (VIS-22) in the two subsets of treated vitiligo patients. 2. To compare the side-effects of NB-UVB therapy occurring in both the subsets of vitiligo patients. Timepoint: 6 months | — |
Primary
| Measure | Time frame |
|---|---|
| 1. To assess the effect of narrow band UV-B therapy in arresting the progression of disease in progressive non-segmental vitiligo patients. 2. To compare the difference in re-pigmentation with NB-UVB therapy between the two subsets of non-segmental vitiligo patients i.e., those with (a) progressive vitiligo and (b) non-progressive vitiligo. Timepoint: 6 Months | — |
Countries
India
Contacts
Public ContactDr Saurabh Bhatia
All India Institute of Medical Sciences, New Delhi
Outcome results
None listed